ADC Therapeutics SA

ADCT Healthcare Biotechnology

ADC Therapeutics SA’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 14.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.17%, EPS grew 78.0%, free cash flow grew 51.0% and total debt rose 1.87%, each against the same quarter a year earlier.

1.41 0.08 −5.37%
Market cap
$190.2M
P/E
0.0×
Fwd P/E
−1.2×
Dividend yield
—
F-score
5/9
Altman Z
−6.67
Beneish M
−2.09
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17
P/E ratio
0.00 0.00 0.00 0.00 0.00 — 0.00 0.00 0.00
Piotroski F-Score
5 3 1 — — — — — —
Altman Z-Score
(6.67) (6.61) (5.55) (2.23) (0.50) — — — —
P/S ratio
5.51 2.73 1.99 1.34 43.21 — 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(14.62) (13.96) (10.76) (4.04) (2.55) — (7.16) (2.14) —
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 — 0.00 0.00 0.00
P/Operating CF
(14.41) (8.85) (4.37) (5.23) (25.15) — (47.62) (47.62) (47.62)
Beneish M-Score
(2.09) (2.67) (5.19) 1.36 — — 2.76 — —
P/B ratio
0.00 0.00 0.00 3.53 9.33 — 13.75 13.75 13.75
Price to Tangible BV
0.00 0.00 0.00 4.31 10.17 — 13.75 13.75 13.75
EV/Sales
3.72 0.99 (0.19) 0.36 33.88 — 0.00 0.00 0.00
EV/EBITDA
0.00 0.00 0.08 0.00 0.00 — 0.00 0.00 0.00
EV/Operating CF
(2.14) (0.57) 0.11 (0.55) (5.21) — (9.22) (9.22) (9.22)
EV/FCF
(2.15) (0.56) 0.11 (0.54) (5.06) — (9.19) (9.19) (9.19)
Quick Ratio
4.14 3.37 4.49 4.87 6.72 10.93 5.89 6.22 12.88
Current Ratio
4.37 3.62 4.97 5.31 7.10 11.14 6.15 6.36 12.91
Net Debt/EBITDA
1.22 1.08 1.02 1.69 1.29 1.51 0.94 1.11 2.88
Debt/Assets
35.73% 35.29% 31.77% 24.89% 21.31% 21.73% 3.65% 0.00% 0.00%
Debt/Equity
(0.62) (0.56) (0.76) 1.54 0.79 0.33 0.05 0.00 0.00
Asset Turnover
0.25 0.21 0.16 0.38 0.06 0.00 0.02 0.02 0.01
Operating CF/Net income
0.99 0.78 0.49 0.88 1.01 0.69 1.04 0.99 0.83
Capex/Depreciation
0.21 (0.26) (0.98) (1.01) (2.42) (1.28) (1.30) (3.34) 0.00
Interest Coverage
(2.35) (2.60) (3.58) (3.36) (14.27) (44.51) (765.38) (44.10) 0.00
ROE
73.43% 89.97% 697.85% (127.99%) (91.72%) (110.28%) (98.13%) (65.58%) (47.87%)
ROA
(44.22%) (46.65%) (56.77%) (28.34%) (40.65%) (75.62%) (80.82%) (163.52%) (42.54%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% (1,729.42%) (11,733.39%) 0.00% 0.00%
Return on Tangible Assets
(60.39%) (73.12%) (87.53%) (44.09%) (50.52%) (59.83%) (111.96%) (101.51%) (36.56%)
Average Days of Receivables
130.63 104.68 132.14 126.89 325.19 0.00 310.09 61.47 390.10
Research and Development Expense of Revenue
127.84% 154.77% 182.76% 88.83% 465.85% 0.00% 4,595.60% 10,378.33% 4,732.45%
Selling, General and Administrative Expense of Revenue
98.25% 121.28% 152.23% 68.36% 401.69% 0.00% 606.92% 769.12% 432.95%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.02 0.02 0.06 0.04 0.00
Share Based Compensation of Revenue
8.49% 9.27% 19.40% 23.50% 178.32% 0.00% 47.74% 41.14% 0.00%
Graham Net Nets
(0.45) (1.21) (1.21) 0.08 0.05 — 0.08 0.08 0.08
Graham Number
6.28 8.80 10.94 0.00 0.00 — 0.00 0.00 0.00
Earnings Yield
(33.99%) (82.91%) (173.37%) (55.99%) (14.85%) — (2.17%) (2.17%) (2.17%)
Free Cash Flow Yield
(31.40%) (64.53%) (88.33%) (50.15%) (15.50%) — (10.08%) (10.08%) (10.08%)
Revenue per Share
0.64 0.73 0.85 2.69 0.44 0.00 0.05 0.02 581.61
Operating CF per Share
(1.11) (1.27) (1.45) (1.77) (3.04) (2.58) (2.47) (2.60) (24,175.81)
Capex per Share
0.00 (0.01) (0.04) (0.03) (0.08) (0.04) (0.04) (0.05) 0.00
Free Cash Flow per Share
(1.11) (1.28) (1.49) (1.80) (3.12) (2.62) (2.51) (2.66) (24,175.81)
Cash per Share
2.06 2.58 3.41 4.18 6.08 6.71 2.34 2.98 84,758.71
Shareholders Equity per Share
(1.46) (2.09) (1.81) 1.02 2.16 5.13 2.26 2.71 80,376.13
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
(1.46) (2.09) (1.81) 1.02 2.16 5.13 2.26 2.71 80,376.13
Free Cash Flow
(140.78) (124.70) (121.90) (140.72) (239.75) (171.54) (123.73) (123.83) (74.94)
Working Capital
236.17 210.79 268.62 353.04 451.25 410.01 102.66 119.73 244.63
Capital Expenditures
0.40 (0.87) (3.22) (2.41) (6.38) (2.81) (2.15) (2.47) (3.16)
Net Current Asset Value
(202.65) (233.37) (166.74) 23.57 73.30 272.26 96.08 117.77 242.39
EV/EBIT
0.00 0.00 0.08 0.00 0.00 — 0.00 0.00 0.00
Capex to Sales
0.00 0.01 0.05 0.01 0.19 0.00 0.92 2.17 0.00
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 — 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.00 0.65 0.58 0.71 0.65 1.34 1.20 0.48 0.30
Cash ROIC
(73.72%) (77.04%) (50.15%) (26.65%) (31.37%) (19.35%) (53.39%) (46.72%) (14.64%)
Accounts Receivable Turnover
3.29 3.11 1.42 4.07 2.06 0.00 2.15 1.08 0.99
Accounts Payable Turnover
0.43 0.35 0.18 0.27 0.16 0.46 0.00 0.00 0.00
Inventory Turnover
1.80 0.65 0.18 0.28 0.00 0.00 — — —
Average Days of Payables
577.59 1,106.17 2,247.01 1,365.68 3,165.25 977.10 0.00 0.00 0.00
Days of Inventory on Hand
263.39 138.11 2,334.76 1,334.94 2,914.24 0.00 — — —
Average Receivables
24.72 22.75 49.08 51.59 16.45 2.34 1.09 1.06 1.82
Average Payables
13.60 16.80 13.96 12.22 8.68 4.30 5.04 7.18 7.18
Average Inventory
3.22 9.21 14.13 11.60 — — — — —
Average Assets
322.57 338.38 422.82 554.42 565.83 325.69 144.12 75.28 211.25
Average Common Equity
(194.24) (175.45) (34.40) 122.77 250.80 223.33 118.70 187.70 187.70

Fold the line items

Columns are period end dates